Human Skin Culture as an Ex Vivo Model for Assessing the Fibrotic Effects of Insulin-Like Growth Factor Binding Proteins

Hidekata Yasuoka¹, Adriana T. Larregina², Yukie Yamaguchi¹ and Carol A. Feghali-Bostwick*,¹,³

Departments of ¹Medicine, ²Dermatology, ²Immunology, and ³Pathology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA

Abstract: Systemic sclerosis (SSc) is a connective tissue disease of unknown etiology. A hallmark of SSc is fibrosis of the skin and internal organs. We recently demonstrated increased expression of IGFBP-3 and IGFBP-5 in primary cultures of fibroblasts from the skin of patients with SSc. In vitro, IGFBP-3 and IGFBP-5 induced a fibrotic phenotype and IGFBP-5 triggered dermal fibrosis in mice. To assess the ability of IGFBPs to trigger fibrosis, we used an ex vivo human skin organ culture model. Our findings demonstrate that IGFBP-3 and IGFBP-5, but not IGFBP-4, increase dermal and collagen bundle thickness in human skin explants, resulting in substantial dermal fibrosis and thickening. These fibrotic effects were sustained for at least two weeks. Our findings demonstrate that human skin ex vivo is an appropriate model to assess the effects of fibrosis-inducing factors such as IGFBPs, and for evaluating the efficacy of inhibitors/therapies to halt the progression of fibrosis and potentially reverse it.

INTRODUCTION

Systemic sclerosis (SSc) is a connective tissue disease whose hallmarks include fibrosis, immune dysregulation, and vascular abnormalities. Dermal fibrosis is a prominent feature of SSc. The most commonly used mouse models of SSc are those arising from genetic mutations or treatment with bleomycin [1]. Although these murine models have proven to be useful for understanding the role of various factors in fibrosis, the ultimate goal of our research is to determine the applicability of our findings in humans who are afflicted with the disease. Furthermore, comparative studies have revealed important anatomical cellular and functional differences between human and mouse skin [2].

Using human skin as an ex vivo organ model of fibrosis has several advantages. First, the skin explants remain viable in culture for at least two weeks. Second, factors and vectors can be readily administered to skin explants via deep and/or superficial injections to affect both the epidermis and dermis or mainly the dermis as these epidermal-dermal explants consist of both epidermis and dermis. Furthermore, skin explants contain all cell types resident in the skin which are capable of exerting their physiological effects on the tissue and neighboring cells. Skin explants have been successfully used to express transgenes in both the epidermal and dermal layers for vaccination and immunotherapeutic purposes [3-6].

Insulin-like growth factor binding proteins (IGFBPs) are a family of six proteins identified for their ability to bind IGF-I with high affinity [7, 8]. We have previously shown that IGFBP-5 is over-expressed in fibrotic lung and skin tissues in patients with SSc and in lung tissues of patients with idiopathic pulmonary fibrosis [9-11]. We have also demonstrated that IGFBP-5 can induce the development of a fibrotic phenotype in vitro in primary fibroblasts and can trigger dermal and pulmonary fibrosis in vivo in murine models [11, 12]. Since our original observation of increased IGFBP-5 levels was made in human samples and the final goal of our studies is the applicability of our findings in humans, we optimized use of an ‘ex vivo’ organ culture model using human skin. The effect of IGFBP-5 on the development of a fibrotic phenotype was examined in this ex vivo skin explant model. Our findings suggest that expressing IGFBP-5, and to a lesser extent IGFBP-3, in normal skin explants results in increased dermal thickness and increased collagen bundle thickness, thus recapitulating the dermal fibrosis seen in patients with SSc.

MATERIALS AND METHODOLOGY

Human Samples: Human skin was obtained from corrective plastic surgery. All tissues were obtained according to the guidelines of the University of Pittsburgh and under a protocol approved by the Institutional Review Board of the University of Pittsburgh. Subcutaneous fat tissue was removed and skin tissue was cut into 1.5 cm x 1.5 cm sections. Adenoviral (Ad) constructs were injected intradermally in a volume of 100 μl 1x PBS. Explants containing complete epidermal and dermal layers were cultured in an air liquid interface with the epidermal and keratin layers side up and exposed to air. The culture medium was replaced daily and consisted of Dulbecco’s modified Eagle’s medium (DMEM) (Mediatech, Herndon, VA) supplemented with 10% FBS (Sigma-Aldrich, St Louis, MO), penicillin, streptomycin, and anti-mycotic agent (Invitrogen Life Technologies, Carlsbad, CA). At the indicated time points, skin tissue was harvested and fixed in 10% formalin prior to embedding in paraffin. Skin punch biopsies were obtained from the clinically affected and unaffected skin of patients with SSc as we have previously described [9, 11].

Adenoviral Constructs: Replication deficient adenoviruses serotype 5 encoding human IGFBP-3, IGFBP-4, or IGFBP-5 were generated as previously described [10]. Adenovirus serotype 5 lacking cDNA was used as a control.
Adenoviruses (1 x 10⁸ pfu) were injected intradermally in a 100 µl volume.

**Immunohistochemistry (IHC):** Six µm sections of paraffin embedded tissues were deparaffinized and endogenous peroxidases were quenched with 3% H₂O₂. Sections were blocked with 5% serum and incubated with polyclonal anti-IGFBP-5 antibody (Gropep Ltd, Adelaide, Australia) or IgG control antibody (Lab Vision Corporation, Fremont, CA). Sections were washed and incubated with biotinylated secondary antibody (Vector Laboratories) and Zymed AEC Red kit (Zymed, San Francisco CA). A light hematoxylin counterstain was used to identify nuclei using Hematoxylin QS (Zymed, San Francisco CA). Bound secondary antibody was detected using the Vectastain ABC kit (Vector Laboratories) and Zymed AEC Red kit (Zymed, San Francisco CA). A light hematoxylin counterstain was used to identify nuclei using Hematoxylin QS (Vector Laboratories). Images were taken on a Nikon Eclipse 800 microscope (Nikon Instruments Inc., Huntley, IL) using identical camera settings.

**Measurement of Skin Dermal and Collagen Bundle Thickness:** Six µm sections of paraffin-embedded skin tissue were stained with hematoxylin and eosin (H & E). Images were taken on a Nikon Eclipse 800 microscope. The thickness of the dermis and of individual collagen bundles was measured using Microsuite™ Software (Olympus America Inc.) as we previously described [11]. Thickness was measured in 5 random fields in each sample. Data are shown in arbitrary units.

**Statistical Analysis:** Dermal and collagen bundle thickness were analyzed using the Mann-Whitney U test.

**RESULTS**

**Increased IGFBP-5 Expression in Skin Tissues of Patients with Systemic Sclerosis**

We had previously shown that primary fibroblasts from skin punch biopsies of patients with SSc express significantly greater IGFBP-5 than healthy donor fibroblasts [9]. Furthermore, fibroblasts from the clinically affected skin of patients with SSc secrete and deposit into their extracellular matrix significantly more IGFBP-5 compared to fibroblasts from the patients’ clinically unaffected skin [11]. To determine whether increased IGFBP-5 expression in skin explants results in increased dermal thickness, we assessed the effect of IGFBP-3 and IGFBP-5 expression on the thickness of the dermis and collagen bundles by IHC using anti-IGFBP-5 antibody. Fig. (2) shows that adenoviral expression of IGFBP-5 in human skin explants ex vivo results in expression intensity and patterns comparable to those observed in SSc patient skin shown in Fig. (1).

**Efficient Expression of IGFBP-5 in Human Skin Explants Results in Increased Dermal Thickness**

To determine whether IGFBP-5 exerts pro-fibrotic effects ex vivo in human skin, skin tissues from four different donors were injected intradermally with Ad expressing IGFBP-3 (Ad3), IGFBP-5 (Ad5) or no cDNA (cAd). Skin tissue was harvested one week post adenoviral administration and sections were stained with hematoxylin and eosin. Skin tissue was harvested one week post adenoviral administration and sections were stained with hematoxylin and eosin. Fig. (3A) shows increased dermal thickness of human skin expressing IGFBP-5, whereas IGFBP-3 induced modest thickening of the skin. The increase in dermal thickness induced by IGFBP-3 and IGFBP-5 was statistically significant (Fig. 3B). Data shown are representative of four independent experiments. Furthermore, IGFBP-3 and IGFBP-5 induced increase in dermal thickness is maintained for two weeks (Fig. 4). Two weeks post adenoviral injection, IGFBP-5 expression resulted in deposition of dermal collagen that was uniformly stained with eosin (Fig. 4).

**Increased Expression of IGFBP-5 in Human Skin Explants Results in Increased Thickness of Individual Collagen Bundles**

In addition to measuring dermal thickness, we assessed the effect of IGFBP-3 and IGFBP-5 expression on the thick-
IGFBP-3 and IGFBP-5 expression resulted in significantly increased collagen bundle thickness and IGFBP-5 resulted in strong staining of collagen bundles with eosin as shown in Fig. (5). The increase in dermal and collagen bundle thickness by the pattern of eosin staining were similar if not identical to those changes observed in the skin of patients with SSc.

Fig. (2). IGFBP-5 is detected in human skin explants injected intradermally with Ad expressing IGFBP-5. IGFBP-5 expression was examined by IHC one week post-adenoviral administration. Immunoperoxidase, 400x.

Fig. (3). IGFBP-5 expression increases dermal thickness. Human skin explants were injected with control Ad (cAd), Ad expressing IGFBP-3 (Ad3) or Ad expressing IGFBP-5 (Ad5). Dermal thickness was assessed one week post-injection. (A) Expression of IGFBP-5 and to a lesser extent IGFBP-3 results in increased dermal thickness. H&E, 40x. (B) Graphical presentation of dermal thickness. * p < 0.02; ** p < 0.04. Data represent four independent experiments using human skin explants from four donors.
Increased Expression of IGFBP-4 Does Not Alter Dermal or Collagen Bundle Thickness

Our previous findings demonstrated that both IGFBP-3 and IGFBP-5 trigger a fibrotic phenotype *in vitro* when applied to primary human fibroblasts [10]. *In vivo*, IGFBP-5 but not IGFBP-3, induced dermal fibrosis in mice [11]. The differential effects of IGFBP-3 in human fibroblasts versus mouse skin may be due to the fact that human rather than
mouse IGFBP-3 was expressed adenovirally, and IGFBP-3 may exert species-specific effects on the matrix. To determine if the induction of fibrosis is a general effect of IGFBPs or a function specific to IGFBP-3 and IGFBP-5, the assays were repeated with skin samples injected with cAd, Ad3, Ad5, and an adenovirus expressing IGFBP-4 (Ad4) as a related protein control. Fig. (6) shows that IGFBP-4, unlike IGFBP-3 and IGFBP-5, does not modulate dermal or collagen bundle thickness of human skin explants.

**DISCUSSION**

Studies have shown that percutaneous permeation of molecules differs in human and rodent skin [13]. Human skin from cosmetic surgery and amputations has been used to assess the transdermal absorption of molecules and its permeation and exerts similar properties to those of pig skin whereas permeation rates of rodent skin are much greater [13]. Human skin explants have been in use as an *ex vivo* organ culture model for a few different applications including the expression of DNA [14], the application of inhibitors to metalloproteinases and other proteinases [15], and treatment with cytokines and growth factors such as IFN-γ [16].

Recently, the use of human skin explants for evaluating the effect of potential therapeutic agents has been reported. In an attempt to interfere with the fibrotic process, Nath *et al.* recently reported using antisense oligonucleotides to reduce Collagen Type I expression *ex vivo* in a skin organ culture model that was maintained for 7 days [17]. To extend the application of human skin explants to *in vivo* gene therapy, Lippin *et al.* obtained skin explants from patients with chronic renal failure and anemia, injected them with an adenovirus expressing human erythropoietin, and reimplanted them into the patients [18]. Increased circulating erythropoietin levels were observed for 14 days and correlated with a rise in reticulocyte count. Although anti-erythropoietin antibodies were detected 3 months following implantation, this approach suggests that use of an *ex vivo* skin organ culture model can be extended to the clinical setting in diseases amenable to gene therapy.

Although numerous reports have focused on the therapeutic applications of human skin *ex vivo*, our findings suggest that: a) human skin explants are valuable as a model to assess the effects of fibrotic factors and b) expression of factors such as IGFBP-5, which trigger a fibrotic phenotype *in vitro* in primary human fibroblasts and *in vivo* in mouse skin and lung tissues [10-12], induces fibrosis *ex vivo* in a skin organ culture model for at least two weeks. Use of skin explants obviates the need for rodent models and renders all findings directly applicable to human diseases such as SSc.

Our findings demonstrate that a) IGFBP-4 does not exert pro-fibrotic effects in human skin, and b) that IGFBP-3 and IGFBP-5 are pro-fibrotic *ex vivo*, although the effects of IGFBP-3 are more modest than those of IGFBP-5 suggesting that IGFBP-5 is a potent pro-fibrotic factor. Thus, IGFBP-3, -4, and -5 exert different effects in the human skin organ culture model. Both IGFBP-3 and IGFBP-5 induce dermal fibro-
sis with IGFBP-5 exerting a more drastic phenotype than IGFBP-3. In contrast, IGFBP-4 expression did not alter dermal or collagen bundle thickness. These three IGFBPs share features that are common to the IGFBP family of proteins: they have conserved N-terminal and C-terminal domains that contain 12 and 6 conserved cysteine residues, respectively. They bind IGF-I with high affinity and modulate its action, either potentiating or inhibiting it [7, 8]. IGFBPs also exhibit important differences. They can exert both IGF-I-dependent and –independent effects and differentially regulate cellular functions such as apoptosis of breast epithelial cells [19]. IGFBP-3 and IGFBP-5 are more structurally similar to each other than to IGFBP-4, a smaller IGFBP that has been shown to inhibit IGF actions [20]. Such differences may be responsible for the different effects of IGFBP’s in the development of dermal fibrosis.

We have previously shown that both IGFBP-3 and IGFBP-5 induce a fibrotic phenotype in vitro defined as increased collagen and fibronectin production and deposition in the ECM of primary human fibroblasts [10]. However, overexpression of human IGFBP-3 in mouse skin, unlike IGFBP-5, did not induce fibrosis [11]. In view of our current findings that both IGFBP-3 and IGFBP-5 induce fibrosis of human skin, it is likely that the inability of human IGFBP-3 to induce fibrosis in rodent skin is due to species-specific activities. Since IGFBP-5 is the most conserved of the IGFBPs, human IGFBP-5 was able to exert similar effects in both human and mouse skin. It is also conceivable that in our human skin explant model, fibrosis in response to IGFBP-3 and IGFBP-5 develops if circulating molecules that can counteract the effects of these IGFBPs are not available. Future directions will address this possibility by maintaining the explants in the presence and absence of autologous serum and or peripheral blood mononuclear cells.

Ideally, once fibrosis in response to IGFBP-5 or other factors is established ex vivo, the explants can be treated with agents specific to the fibrotic factors of interest for a targeted therapeutic approach. Thus, the ex vivo human skin model is valuable for assessing the fibrotic activity of molecules of interest as well as evaluating the efficacy of anti-fibrotic therapies in a milieu that renders the findings directly applicable to human disease.

CONCLUSION

In conclusion, our findings demonstrate that skin explants can serve as a suitable ex vivo organ model to assess the role of IGFBP-3 and IGFBP-5 in the development of dermal fibrosis. Adenoviral expression of IGFBP-5 administered intradermally results in IGFBP-5 expression levels and distribution comparable to those seen in SSC patient skin. Furthermore, IGFBP-5, and to a lesser extent IGFBP-3, trigger fibrosis ex vivo in a human skin organ culture model. Thus, human skin explants are a suitable model to address the role of pathogenic molecules in the development of fibrosis and to assess the role of these molecules and potentially therapeutic factors in human disease.

ACKNOWLEDGEMENT

Supported by National Institutes of Health grant RO1AR058040.

REFERENCES

[1] Denton CP, Abraham DJ. Transgenic analysis of scleroderma: understanding key pathogenic events in vivo. Autoimmun Rev 2004; 3: 285-93.
[2] Rowden G. Macrophages and dendritic cells in the skin. The skin immune system (SIS). In: Bos JD Ed, Cutaneous Immunology and Clinical Immunodermatology. New York, CRC Press,1997; 7: 104-46.
[3] Larregina AT, Watkins SC, Erdos G, et al. Direct transfection and activation of human cutaneous dendritic cells. Gene Ther 2001; 8: 608-17.
[4] Morelli A, Larregina A, Chuluyan E, Kolkowski E, Fainboim L. Functional expression and modulation of CSa receptor (CD88) on skin dendritic cells. Adv Exp Med Biol 1997; 417: 133-8.
[5] Larregina AT, Morelli AE, Spencer LA, et al. Dermal-resident CD14+ cells differentiate into Langerhans cells. Nat Immunol 2001; 2: 1151-8.
[6] Morelli AE, Rubin JP, Erdos G, et al. CD4+ T cell responses elicited by different subsets of human skin migratory dendritic cells. J Immunol 2005; 175: 7905-15.
[7] Duan C. Specifying the cellular responses to IGF signals: roles of IGF-binding proteins. J Endocrinol 2002; 175: 41-54.
[8] Jones JJ, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 1995; 16: 3-34.
[9] Feghali CA, Wright TM. Identification of multiple, differentially expressed messenger RNAs in dermal fibroblasts from patients with systemic sclerosis. Arthritis Rheum 1999; 42: 1451-7.
[10] Pilewski JM, Liu L, Henry AC, Knauer AV, Feghali-Bostwick CA. Insulin-like growth factor binding proteins 3 and 5 are overexpressed in idiopathic pulmonary fibrosis and contribute to extracellular matrix deposition. Am J Pathol 2005; 166: 399-407.
[11] Yasuoka H, Jukic DM, Zhou Z, Choi AM, Feghali-Bostwick CA. Insulin-like growth factor binding protein 5 induces skin fibrosis: A novel murine model for dermal fibrosis. Arthritis Rheum 2006; 54: 3001-10.
[12] Yasuoka H, Zhou Z, Pilewski JM, Oury TD, Choi AM, Feghali-Bostwick CA. Insulin-like growth factor binding protein-5 induces pulmonary fibrosis and triggers mononuclear cellular infiltration. Am J Pathol 2006; 169: 1633-42.
[13] Godin B, Toutou E. Transdermal skin delivery: Predictions for humans from in vivo, ex vivo and animal models. Adv Drug Deliv Rev 2007; 59: 1152-61.
[14] Hengge UR, Walker PS, Vogel JC. Expression of naked DNA in human, pig, and mouse skin. J Clin Invest 1996; 97: 2911-16.
[15] Mirastchijski U, Impola U, Karsdal MA, Saarialho-Kere U, Ägren MS. Matrix metalloproteinase inhibitor BB-3103 unlike the serine protease inhibitor aprotinin abrogates epidermal healing of human skin wounds ex vivo. J Invest Dermatol 2002; 118: 55-64.
[16] Hattori N, Komine M, Yano S, et al. Interferon-γ, a strong suppressor of cell proliferation, induces upregulation of keratin K6, one of the inflammatory- and proliferation-associated keratins. J Invest Dermatol 2002; 119: 403-10.
[17] Nath RK, Xiong W, Humphries AD, Beri R. Treatment with antisenes oligonucleotide reduces the expression of type I collagen in a human-skin organ-wound model. Ann Plast Surg 2007; 59: 699-706.
[18] Lippin Y, Drumizki-Halihel M, Brill-Almon E, et al. Human erythropoietin gene therapy for patients with chronic renal failure. Blood 2005; 106: 2280-6.
[19] Perks CM, Bowen S, Gill ZP, Newcomb PV, Holly JMP. Differential IGF-independent effects of insulin-like growth factor binding proteins (1-6) on apoptosis of breast epithelial cells. J Cell Biochem 1999; 75: 652-64.
[20] Wetterau LA, Moore MG, Lee KW, Shim ML, Cohen P. Novel aspects of the insulin-like growth factor binding proteins. Mol Genet Metab 1999; 68: 161-81.